This project focuses on the altered metabolism of prostate cancer cells, particularly their increased consumption of ATP, NADPH, and glucose to support rapid growth, invasivity and migratory capacity. A key aspect of this metabolic reprogramming is the Warburg effect, where tumour cells rely on aerobic glycolysis even in the presence of oxygen. The Caveolin-1 (Cav-1) protein plays a significant role in these metabolic changes, acting either as a tumour suppressor or oncogene, depending on the cell type and disease stage. Cav-1 also influences cell signalling pathways, impacting the surrounding tumour microenvironment (TME). To better understand Cav-1’s role in cancer metabolism, this project uses CRISPR/Cas9 technology to create knock-out and knock-in cell lines, enabling a detailed study of Cav-1’s effects on ATP production, the balance between glycolysis and oxidative phosphorylation, and cellular behaviour such as migration and invasion. The project further employs advanced three-dimensional (3D) BioSilk scaffolds to provide a more accurate model of the TME, offering a valuable alternative to traditional 2D cultures and spheroid models. Through these efforts, the project aims to gather critical preliminary data for future large-scale studies.